Opinions in Oncology – Lung cancer

A series of print publications entitled: ‘Opinions in Oncology’ entirely dedicated to the first line treatment of non small cell lung cancer (NSCLC).

Each publication consists of a state of the art introduction on the topic at hand followed by interviews with leading key opinion leaders within pulmonary oncology who discuss new developments relevant for daily clinical practice.

Lung cancer

Pulmonologists and medical oncologists in the Netherlands

Informing oncologists and pulmonologists about latest results of the LUX-Lung study that compared the efficacy of afatinib with gefitinib as first line treatment for NSCLC.

Two leading experts, Professor J. Aerts, PhD, MD (Amphia Ziekenhuis in Breda & Erasmus Medical Centre in Rotterdam) and Professor E. Smit, PhD, MD (Amsterdam University Medical Centre, location VUmc and Dutch Cancer Institute -NKI) comment the results of this study and give ‘how-to-treat’ advice to readers.

The ‘awareness’ of doctors realizing the higher efficacy of afatinib versus gefitinib as shown in the LUX-Lung study, increased amongst target doctors thus favoring afatinib as their drug of choice.